AIM:阿司匹林可预防心血管疾病和大肠癌,但究竟有无其他危害?

2016-04-12 QQduhp 译 MedSci原创

有证据表明,阿司匹林是预防心血管疾病(CVD)和结肠直肠癌(CRC)有效的一级药物,但是却增加了胃肠(GI)和脑出血的风险。原始出处:Steven P. Dehmer,Michael V. Maciosek,Thomas J. Flottemesch,et al.Aspirin for the Primary Prevention of Cardiovascular Disease and Col

有证据表明,阿司匹林是一级预防心血管疾病(CVD)和结肠直肠癌(CRC)有效的药物,但是却增加了胃肠(GI)和脑出血的风险。

该研究的目的是评估在跨临床相关的年龄,性别和心血管疾病高危人群中,常规服用阿司匹林的益处和危害。

来自美国的研究人员进行了一项利用微观仿真模型的决策分析。该分析包括3项系统的证据审核。

该研究的目标人群是年龄在40至79岁,10年CVD风险为20%或以下,并没有心血管疾病病史,无GI或脑出血升高的风险的男性和女性,并且禁忌使用阿司匹林。时间跨度为整个生命周期,20年以及10年。干预措施为服用低剂量的阿司匹林(≤100mg/d)。

主要结果是在净生命年和质量调整生命年中衡量寿命长度和生活质量。益处包括减少的非致死性心梗,非致死性缺血性卒中,致命性CVD,CRC发病率以及CRC死亡率。危害包括增加的致死性和非致死性GI出血和出血性卒中危险。

大多数年龄在40〜69岁开始服用阿司匹林的成年人,对于终生净质量调整生命年是有益的,大多数具有较高的心血管疾病的风险的年龄在40〜59岁和60〜69岁的男性和女性开始服用阿司匹林后预期寿命延长。在最初的10至20年中,在70岁开始服用阿司匹林的人危害可能大于益处。

这些结果对于出血性卒中和心血管疾病死亡的相对危险度是最敏感的,但受所有相关风险评估,基线GI出血发生率和病死率的影响,并且阿司匹林的使用与负效用相关。

该研究的限制性为年龄对于阿司匹林的效果影响是不确定的。对于卒中的益处也是保守估计的。消化道出血发病率和病死率也只能说明年龄和性别的原因。

在年轻的年龄(40〜69岁)和具有较高的心血管疾病风险的人中,终生服用阿司匹林用于一级预防具有最大的益处。

原始出处:

Steven P. Dehmer,Michael V. Maciosek,Thomas J. Flottemesch,et al.Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer,Ann Intern Med,2016.4.12

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=139441, encodeId=655613944193, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:17 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=80663, encodeId=dec180663d5, content=get, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er7gGJY7ibia1wDTTwTL7vXbqvekMBTHAsd3KZ7btXM9tnHuicI2LdxJtIiccXeDCiaTvzkwMuribZ9oHVA/0, createdBy=c7b81713099, createdName=木水晶, createdTime=Fri Apr 22 15:06:00 CST 2016, time=2016-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78013, encodeId=b241e80134f, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:17:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78014, encodeId=791fe801464, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:17:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497981, encodeId=01e8149e98141, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Apr 13 23:48:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77592, encodeId=68f5e75927a, content=年龄段的研究对服药有指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Wed Apr 13 08:15:00 CST 2016, time=2016-04-13, status=1, ipAttribution=)]
    2016-10-03 1e10c84am36(暂无匿称)

    深度好文,值得关注

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=139441, encodeId=655613944193, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:17 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=80663, encodeId=dec180663d5, content=get, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er7gGJY7ibia1wDTTwTL7vXbqvekMBTHAsd3KZ7btXM9tnHuicI2LdxJtIiccXeDCiaTvzkwMuribZ9oHVA/0, createdBy=c7b81713099, createdName=木水晶, createdTime=Fri Apr 22 15:06:00 CST 2016, time=2016-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78013, encodeId=b241e80134f, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:17:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78014, encodeId=791fe801464, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:17:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497981, encodeId=01e8149e98141, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Apr 13 23:48:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77592, encodeId=68f5e75927a, content=年龄段的研究对服药有指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Wed Apr 13 08:15:00 CST 2016, time=2016-04-13, status=1, ipAttribution=)]
    2016-04-22 木水晶

    get

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=139441, encodeId=655613944193, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:17 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=80663, encodeId=dec180663d5, content=get, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er7gGJY7ibia1wDTTwTL7vXbqvekMBTHAsd3KZ7btXM9tnHuicI2LdxJtIiccXeDCiaTvzkwMuribZ9oHVA/0, createdBy=c7b81713099, createdName=木水晶, createdTime=Fri Apr 22 15:06:00 CST 2016, time=2016-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78013, encodeId=b241e80134f, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:17:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78014, encodeId=791fe801464, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:17:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497981, encodeId=01e8149e98141, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Apr 13 23:48:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77592, encodeId=68f5e75927a, content=年龄段的研究对服药有指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Wed Apr 13 08:15:00 CST 2016, time=2016-04-13, status=1, ipAttribution=)]
    2016-04-14 李继凯

    高大上的文章

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=139441, encodeId=655613944193, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:17 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=80663, encodeId=dec180663d5, content=get, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er7gGJY7ibia1wDTTwTL7vXbqvekMBTHAsd3KZ7btXM9tnHuicI2LdxJtIiccXeDCiaTvzkwMuribZ9oHVA/0, createdBy=c7b81713099, createdName=木水晶, createdTime=Fri Apr 22 15:06:00 CST 2016, time=2016-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78013, encodeId=b241e80134f, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:17:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78014, encodeId=791fe801464, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:17:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497981, encodeId=01e8149e98141, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Apr 13 23:48:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77592, encodeId=68f5e75927a, content=年龄段的研究对服药有指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Wed Apr 13 08:15:00 CST 2016, time=2016-04-13, status=1, ipAttribution=)]
    2016-04-14 李继凯

    值得学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=139441, encodeId=655613944193, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:17 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=80663, encodeId=dec180663d5, content=get, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er7gGJY7ibia1wDTTwTL7vXbqvekMBTHAsd3KZ7btXM9tnHuicI2LdxJtIiccXeDCiaTvzkwMuribZ9oHVA/0, createdBy=c7b81713099, createdName=木水晶, createdTime=Fri Apr 22 15:06:00 CST 2016, time=2016-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78013, encodeId=b241e80134f, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:17:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78014, encodeId=791fe801464, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:17:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497981, encodeId=01e8149e98141, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Apr 13 23:48:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77592, encodeId=68f5e75927a, content=年龄段的研究对服药有指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Wed Apr 13 08:15:00 CST 2016, time=2016-04-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=139441, encodeId=655613944193, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:17 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=80663, encodeId=dec180663d5, content=get, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er7gGJY7ibia1wDTTwTL7vXbqvekMBTHAsd3KZ7btXM9tnHuicI2LdxJtIiccXeDCiaTvzkwMuribZ9oHVA/0, createdBy=c7b81713099, createdName=木水晶, createdTime=Fri Apr 22 15:06:00 CST 2016, time=2016-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78013, encodeId=b241e80134f, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:17:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78014, encodeId=791fe801464, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:17:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497981, encodeId=01e8149e98141, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Apr 13 23:48:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77592, encodeId=68f5e75927a, content=年龄段的研究对服药有指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Wed Apr 13 08:15:00 CST 2016, time=2016-04-13, status=1, ipAttribution=)]
    2016-04-13 Wechat4343a314

    年龄段的研究对服药有指导意义

    0

相关资讯

JAMA:PCI术后1年,还需要继续双抗血小板治疗吗?

经皮冠状动脉介入术(PCI)后进行双重抗血小板治疗可减少缺血性风险,但会增加出血风险。研究者进行了一项试验,建立一个临床决策工具,以识别PCI术后1年持续使用噻吩并吡啶类抗血小板药物的优劣。该研究纳入了11个国家的11 648名患者(DAPT 研究),根据PCI术后12-30个月的缺血和出血风险建立预测规则,再经过8136名患者进行验证(PROTECT)。先进行长达12个月的噻吩并吡啶+阿司匹林治

JAMA Oncol:定期低剂量服用阿司匹林真的可降低民众患结直肠癌风险

背景美国预防医学会建议美国成人服用阿司匹林预防结直肠癌和心血管疾病。然而,使用阿司匹林与民众患癌风险和潜在的副作用之间的关系尚不清楚。 目的该研究的目的是探究服用阿司匹林的潜在好处及对特定癌症的预防作用。研究人员通过两项美国大型前瞻性群组研究即护士健康研究(1980-2010)和医务人员随访研究(1986-2012),对135965名医务人员(88084名女性和47881名男性)进行了随访,每2年

Obstet Gynecol:备孕期间可以服用低剂量阿司匹林吗?

近期发表在Obstetrics and Gynecology的研究称,受孕前服用低剂量阿司匹林,无论是对孕妇还是胎儿都具有良好的耐受性,不过研究也指出,罕见和严重的并发症无法排除。众所周知低剂量阿司匹林不仅对先兆子痫有益,对妊娠结局也会有潜在的益处。那么孕前使用低剂量阿司匹林,会不会对母婴有什么影响呢?研究者对阿司匹林对妊娠和生殖影响试验的数据进行了二次分析。该研究为多中心、随机、双盲、安慰剂对照

Hepatology:阿司匹林可降低胆管癌风险

阿司匹林能预防胆管癌(CCA)吗?研究者对CCA患者进行了一项基于医院的病例对照研究,探究阿司匹林对CCA的影响,以及不同CCA类型的危险因素。研究共纳入了2000-2014年梅约诊所的2395名CCA患者,其中1169名为肝内CCA患者,995名为肝门部CCA患者,231名为远端CCA患者。根据年龄、性别、种族和居住地按2:1匹配了4769名对照组。CCA组和对照组分别为591 (24.7%)名

JAMA Oncol:常规性地使用阿司匹林能够帮助降低癌症发病风险

(图片摘自www.sciencealert.com)长久以来,阿司匹林被认为对人类健康有许多益处。如今,一项最近的研究认为这一药物能够有效降低人们患癌症的风险。根据哈佛大学研究者们的研究结果,长期服用阿司匹林能够降低3%的癌症发病风险,其中主要包括结肠癌与其它癌症类型。虽然科学家们之前已经知道阿司匹林对这些特定癌症类型具有一定的疗效,但这还是首次发现其也能帮助降低癌症的发病风险。科学家们首先利用美

NEJM:行冠状动脉手术前是否应停用阿司匹林药物?

以往的研究中发现,大多数的冠状动脉疾病患者都会服用阿司匹林预防心肌梗死和中风等。而服用阿司匹林对接受手术的患者有出血风险,对于在行冠状动脉手术前是否应该停止服用阿司匹林,目前人们尚未清楚。